Polosukhina et al. further highlighted the critical role of epithelial-derived CCL11 in modulating colitis-associated carcinogenesis, proposing anti-CCL11 antibody therapy as a promising strategy for both inflammatory bowel disease management and cancer chemoprevention [67]. This evidence concerns the gene CCL11 and colitis.